C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992.

BACKGROUND Inflammatory reactions in coronary plaques play an important role in the pathogenesis of acute atherothrombotic events; inflammation elsewhere is also associated with both atherogenesis generally and its thrombotic complications. Recent studies indicate that systemic markers of inflammation can identify subjects at high risk of coronary events. METHODS AND RESULTS We used a sensitive immunoradiometric assay to examine the association of serum C-reactive protein (CRP) with the incidence of first major coronary heart disease (CHD) event in 936 men 45 to 64 years of age. The subjects, who were sampled at random from the general population, participated in the first MONICA Augsburg survey (1984 to 1985) and were followed for 8 years. There was a positive and statistically significant unadjusted relationship, which was linear on the log-hazards scale, between CRP values and the incidence of CHD events (n=53). The hazard rate ratio (HRR) of CHD events associated with a 1-SD increase in log-CRP level was 1.67 (95% CI, 1.29 to 2. 17). After adjustment for age, the HRR was 1.60 (95% CI, 1.23 to 2. 08). Adjusting further for smoking behavior, the only variable selected from a variety of potential confounders by a forward stepping process with a 5% change in the relative risk of CRP as the selection criterion, yielded an HRR of 1.50 (95% CI, 1.14 to 1.97). CONCLUSIONS These results confirm the prognostic relevance of CRP, a sensitive systemic marker of inflammation, to the risk of CHD in a large, randomly selected cohort of initially healthy middle-aged men. They suggest that low-grade inflammation is involved in pathogenesis of atherosclerosis, especially its thrombo-occlusive complications.

[1]  K. Kaikita,et al.  Tissue factor expression on macrophages in coronary plaques in patients with unstable angina. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[2]  L. Chambless,et al.  The cardiovascular risk factor profile in the study area Augsburg. Results from the first MONICA survey 1984/85. , 2009, Acta medica Scandinavica. Supplementum.

[3]  C. Yutani,et al.  Immunohistochemical localization of C‐reactive protein‐binding sites in human atherosclerotic aortic lesions by a modified streptavidin‐biotin‐staining method , 1995, Pathology international.

[4]  D. Spodick,et al.  Association of acute respiratory symptoms with onset of acute myocardial infarction: prospective investigation of 150 consecutive patients and matched control patients. , 1984, The American journal of cardiology.

[5]  J. Mehta,et al.  Increased neutrophil elastase release in unstable angina pectoris and acute myocardial infarction. , 1990, Journal of the American College of Cardiology.

[6]  L. Kuller,et al.  ORIGINAL CONTRIBUTIONS Relation of C-Reactive Protein and Coronary Heart Disease in the MRFIT Nested Case-Control Study , 1996 .

[7]  C. Mold,et al.  Sublytic complement attack exposes C-reactive protein binding sites on cell membranes. , 1994, Journal of immunology.

[8]  S Greenland,et al.  Modeling and variable selection in epidemiologic analysis. , 1989, American journal of public health.

[9]  P. Berger Symptoms of chronic bronchitis and the risk of coronary disease , 1997 .

[10]  A. Döring,et al.  Leisure-time physical activity but not work-related physical activity is associated with decreased plasma viscosity. Results from a large population sample. , 1997, Circulation.

[11]  David R. Cox,et al.  Regression models and life tables (with discussion , 1972 .

[12]  M. Pepys,et al.  C-reactive protein: binding to lipids and lipoproteins. , 1985, International review of experimental pathology.

[13]  Ronald J. Prineas,et al.  The Minnesota code manual of electrocardiographic findings : standards and procedures for measurement and classification , 1982 .

[14]  F. Wolfe,et al.  The mortality of rheumatoid arthritis. , 1994, Arthritis and rheumatism.

[15]  M. Pepys,et al.  Rapid automated high sensitivity enzyme immunoassay of C-reactive protein. , 1998, Clinical chemistry.

[16]  I. Sartori Hemostatic Factors and the Risk of Myocardial Infarction or Sudden Death in Patients with Angina Pectoris , 1996 .

[17]  L H Kuller,et al.  Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[18]  P. Vokonas,et al.  Periodontal Disease and Cardiovascular Disease. , 1996, Journal of periodontology.

[19]  Principal Investigators,et al.  The World Health Organization MONICA project (monitoring trends and determinants in cardiovascular disease): a major international collabaration , 1988 .

[20]  J. Danesh,et al.  Chronic infections and coronary heart disease: is there a link? , 1997, The Lancet.

[21]  Leukocytes and the risk of ischemic diseases. , 1987, JAMA.

[22]  A. Becker,et al.  Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. , 1994, Circulation.

[23]  S Böthig,et al.  WHO MONICA Project: objectives and design. , 1989, International journal of epidemiology.

[24]  K. Mattila Viral and bacterial infections in patients with acute myocardial infarction , 1989, Journal of internal medicine.

[25]  U. Keil,et al.  Case finding, data quality aspects and comparability of myocardial infarction registers: results of a south German register study. , 1991, Journal of clinical epidemiology.

[26]  J. Volanakis COMPLEMENT ACTIVATION BY C‐REACTIVE PROTEIN COMPLEXES * , 1982, Annals of the New York Academy of Sciences.

[27]  R. Ross The pathogenesis of atherosclerosis: a perspective for the 1990s , 1993, Nature.

[28]  R. Tracy,et al.  Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. , 1997, Clinical chemistry.

[29]  I. Knezevic,et al.  [Biological standardization]. , 1972, Harefuah.

[30]  M. Pepys,et al.  Immunohistochemical studies of c‐reactive protein and apolipoprotein b in inflammatory and arterial lesions , 1985, Journal of Pathology.

[31]  J. Kruskal,et al.  Fibrin and fibrinogen-related antigens in patients with stable and unstable coronary artery disease. , 1987, The New England journal of medicine.

[32]  Harry,et al.  C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. , 1993, Blood.

[33]  J. Volanakis,et al.  Interaction of C-reactive protein with artificial phosphatidylcholine bilayers and complement. , 1981, Journal of immunology.

[34]  M. Pepys,et al.  Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease. , 1993, The Journal of clinical investigation.

[35]  A. Rebuzzi,et al.  The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. , 1994, The New England journal of medicine.

[36]  G. Bray Definition, measurement, and classification of the syndromes of obesity. , 1978, International journal of obesity.

[37]  H. Gewurz,et al.  EFFECTS OF C‐REACTIVE PROTEIN (CRP) ON PLATELET FUNCTION * , 1982, Annals of the New York Academy of Sciences.

[38]  E. G. Buckley OXFORD TEXTBOOK OF MEDICINE (2nd edition) , 1987 .

[39]  S. Thompson,et al.  Production of C-reactive protein and risk of coronary events in stable and unstable angina , 1997, The Lancet.

[40]  G. Vercellotti,et al.  C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor , 1993 .

[41]  M. Kornitzer,et al.  The World Health Organization MONICA Project (Monitoring trends and determinants in cardiovascular disease): A major international Collaboration , 1988 .

[42]  J. Gauldie,et al.  The acute phase response. , 1994, Immunology today.

[43]  V. Fuster,et al.  Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. , 1997, Circulation.

[44]  W. Koenig,et al.  C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[45]  W. Weintraub,et al.  Elevation of C-reactive protein in "active" coronary artery disease. , 1990, The American journal of cardiology.

[46]  H. Tunstall-Pedoe,et al.  Myocardial Infarction and Coronary Deaths in the World Health Organization MONICA Project: Registration Procedures, Event Rates, and Case‐Fatality Rates in 38 Populations From 21 Countries in Four Continents , 1994, Circulation.

[47]  P. Ridker,et al.  Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. , 1997, The New England journal of medicine.

[48]  D. Strachan,et al.  C Reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study , 1996, BMJ.

[49]  J. Wright,et al.  Expression of C-reactive protein by alveolar macrophages. , 1996, Journal of immunology.

[50]  K. Beaman,et al.  Extrahepatic transcription of human C-reactive protein , 1991, The Journal of experimental medicine.

[51]  E. Bramucci,et al.  Tissue-factor antigen and activity in human coronary atherosclerotic plaques , 1997, The Lancet.

[52]  S. Thompson,et al.  Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. , 1996, Circulation.

[53]  David J. Weatherall,et al.  Oxford textbook of medicine , 1996 .